Overview

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Treatments:
Antibodies
Antibodies, Monoclonal